Lineage Cell Therapeutics/$LCTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lineage Cell Therapeutics
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Ticker
$LCTX
Sector
Primary listing
AMEX
Industry
Biotechnology
Headquarters
Employees
74
Website
LCTX Metrics
BasicAdvanced
$233M
-
-$0.08
1.42
-
Price and volume
Market cap
$233M
Beta
1.42
52-week high
$1.21
52-week low
$0.37
Average daily volume
3.2M
Financial strength
Current ratio
3.819
Quick ratio
3.676
Long term debt to equity
1.37
Total debt to equity
2.89
Profitability
EBITDA (TTM)
-20.724
Gross margin (TTM)
-34.17%
Net profit margin (TTM)
-169.57%
Operating margin (TTM)
-223.10%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-12.10%
Return on equity (TTM)
-21.75%
Valuation
Price to revenue (TTM)
22.518
Price to book
2.95
Price to tangible book (TTM)
10.68
Price to free cash flow (TTM)
-9.431
Free cash flow yield (TTM)
-10.60%
Free cash flow per share (TTM)
-0.108
Growth
Revenue change (TTM)
19.42%
Earnings per share change (TTM)
-42.90%
3-year revenue growth (CAGR)
1.32%
10-year revenue growth (CAGR)
5.79%
3-year earnings per share growth (CAGR)
-35.86%
10-year earnings per share growth (CAGR)
-17.71%
What the Analysts think about LCTX
Analyst ratings (Buy, Hold, Sell) for Lineage Cell Therapeutics stock.
LCTX Financial Performance
Revenues and expenses
LCTX Earnings Performance
Company profitability
LCTX News
AllArticlesVideos
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
Business Wire·1 month ago
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
Business Wire·2 months ago
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lineage Cell Therapeutics stock?
Lineage Cell Therapeutics (LCTX) has a market cap of $233M as of August 01, 2025.
What is the P/E ratio for Lineage Cell Therapeutics stock?
The price to earnings (P/E) ratio for Lineage Cell Therapeutics (LCTX) stock is 0 as of August 01, 2025.
Does Lineage Cell Therapeutics stock pay dividends?
No, Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Lineage Cell Therapeutics dividend payment date?
Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lineage Cell Therapeutics?
Lineage Cell Therapeutics (LCTX) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.